Summit Therapeutics Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. Unaudited results; amounts below are in U.S. dollars. Summit is a clinical-stage biopharmaceutical company with no approved products.
Financial results and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $0.235m | $0.057m | $0.485m | $0.249m |
| Research and development expense | $9.008m | $23.923m | $29.564m | $42.302m |
| General and administrative expense | $6.933m | $5.984m | $13.592m | $10.169m |
| Operating loss | $12.692m | $23.730m | $34.850m | $40.653m |
| Net loss | $16.771m | $24.416m | $38.168m | $41.904m |
| Loss per share | $0.17 | $0.27 | $0.38 | $0.48 |
Revenue came from the Eurofarma license and commercialization agreement. Other operating income was $3.014m in Q2 and $7.821m for the half year, primarily from BARDA funding, U.K. R&D tax credits, and CARB-X grants. Gross margin is not presented as a meaningful metric in the filing.
Research and development expense fell mainly because of lower ridinilazole Phase III clinical and manufacturing activity; spending on the SMT-738 antibiotic program increased. Lower U.K. tax-credit income also reduced other operating income. Q2 other expense rose to $4.079m from $0.686m, primarily due to foreign-currency losses.
At June 30, cash was $57.335m; current assets were $79.398m and current liabilities $15.173m. R&D tax-credit receivables totaled $16.455m. Total liabilities were $44.401m, including a $25.312m related-party note payable; stockholders’ equity was $51.317m. Six-month operating cash use was $38.218m, investing cash use $0.654m, and financing cash provided $25.187m. No cash interest was paid on the 2022 note during the half year.
Material changes and subsequent events
- After quarter-end, the August 2022 rights offering raised approximately $100m gross through the sale of approximately 103m shares at $0.97 per share; issuance costs were approximately $0.1m. The company repaid the $25m related-party note plus accrued interest on August 10, 2022. The offering materially increased shares outstanding and diluted existing holders.
- Management stated that, after considering the rights-offering proceeds and note repayment, available resources were expected to fund operating costs and working capital for more than 12 months from the filing date. Summit nevertheless expects continuing losses and may need further financing.
- At a July 12 FDA Type C meeting, Summit discussed a possible ridinilazole development path that would involve at least one additional clinical trial. The company was evaluating that path; the filing gives no definitive trial plan or timing.
- BARDA’s final independent option was not exercised. Its contract was extended through December 2022 at no cost solely to close out activities. CARB-X’s existing arrangement concluded June 30; Summit was negotiating a new agreement for the remaining program.
- Shareholders approved increasing authorized common shares from 250m to 350m and adding 8m shares to the 2020 Stock Incentive Plan.
Outlook, risks, and contingencies
Summit expects significant operating losses for the foreseeable future and needs additional capital until it can generate substantial revenue and achieve profitability. Financing may not be available on acceptable terms; equity financing may dilute holders, while debt or partnerships could impose restrictions or require relinquishing rights. The company was also exploring potential business-development opportunities, but gave no assurance that discussions would result in transactions.
Key business risks include the uncertain next steps and regulatory path for ridinilazole following the Phase III Ri-CoDIFy results, dependence on grants and tax credits, and the possibility that funding constraints could delay, reduce, or end development programs. The filing disclosed a Nasdaq minimum-bid-price risk: the stock had closed below $1.00 on 10 of the 30 trading days ended August 4, 2022. Summit reported no material legal proceedings and no material changes to previously disclosed risk factors other than those described in the filing.
Important facts for investors to verify
- FDA meeting minutes, the proposed additional ridinilazole trial, and its costs, timing, and financing.
- Final rights-offering share issuance, proceeds net of costs, note repayment, and resulting dilution and share count.
- Updated cash runway and the assumptions behind management’s greater-than-12-month estimate.
- Whether Summit and CARB-X reach a new funding agreement, and the remaining availability of BARDA and U.K. tax-credit funding.
- Nasdaq bid-price compliance and any further capital-raising or partnership developments.